Shares of Astellas Pharma Inc. (OTCMKTS:ALPMY – Get Free Report) crossed above its fifty day moving average during trading on Friday . The stock has a fifty day moving average of $9.58 and traded as high as $10.03. Astellas Pharma shares last traded at $9.63, with a volume of 81,803 shares.
Astellas Pharma Trading Down 1.6%
The firm has a market capitalization of $17.43 billion, a P/E ratio of -43.77 and a beta of 0.23. The business has a 50-day moving average price of $9.58 and a 200-day moving average price of $9.70. The company has a quick ratio of 0.80, a current ratio of 1.04 and a debt-to-equity ratio of 0.39.
Astellas Pharma (OTCMKTS:ALPMY – Get Free Report) last issued its earnings results on Friday, April 25th. The company reported $0.27 EPS for the quarter, beating the consensus estimate of $0.15 by $0.12. The company had revenue of $3.22 billion for the quarter, compared to the consensus estimate of $3.02 billion. Astellas Pharma had a negative net margin of 3.10% and a positive return on equity of 13.69%. Analysts anticipate that Astellas Pharma Inc. will post 0.42 earnings per share for the current year.
Astellas Pharma Company Profile
Astellas Pharma Inc manufactures, markets, and imports and exports pharmaceuticals in Japan and internationally. The company provides XTANDI, a treatment for prostate cancer; XOSPATA, a treatment for patients who have relapsed or refractory acute myeloid leukemia with a FLT3 mutation; and PADCEV, a treatment for patients with metastatic urothelial cancer.
Featured Articles
- Five stocks we like better than Astellas Pharma
- How to Choose Top Rated Stocks
- IBM Up 10 Days in a Row: What’s Driving the Winning Streak?
- Insider Buying Explained: What Investors Need to Know
- Upstart Stock’s Bull Case Just Got a Lot Stronger
- Biggest Stock Losers – Today’s Biggest Percentage Decliners
- Higher Gulf Oil Output Puts These Energy Names in Play
Receive News & Ratings for Astellas Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Astellas Pharma and related companies with MarketBeat.com's FREE daily email newsletter.